Tocilizumab

In the US, Tocilizumab (tocilizumab systemic) is a member of the drug class interleukin inhibitors and is used to treat Juvenile Idiopathic Arthritis and Rheumatoid Arthritis.

US matches:

• Tocilizumab


• Tocilizumab Intravenous


• Tocilizumab Injection

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L04AC07

CAS registry number (Chemical Abstracts Service)

0375823-41-9

Chemical Formula

C6428-H9976-N1720-O2018-S42

Molecular Weight

144985

Therapeutic Categories

Immunomodulator

Monoclonal antibody

Chemical Name

immunoglobulin G1, anti-(human interleukin 6 receptor) (human-mouse monoclonal MRA heavy chain), disulfide with human-mouse monoclonal MRA kappa-chain, dimer (WHO)

Foreign Names

• Tocilizumabum (Latin)
• Tocilizumab (German)
• Tocilizumab (French)
• Tocilizumab (Spanish)

Generic Names

• Tocilizumab (OS: USAN)
• Atlizumab (IS)
• MRA (IS)
• R-1569 (IS)

Brand Names

• Actemra
  Chugai, Japan; Genentech, United States; Roche, Australia; Roche, Switzerland; Roche, Russian Federation



• RoActemra
  Roche, Germany; Roche, Spain; Roche, United Kingdom; Roche, Ireland; Roche, Sweden; Roche, Slovakia

International Drug Name Search

Glossary

IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.